Tikun Therapeutics is a private, pre-revenue biotech company operating as a Public Benefit Corporation with an exclusive focus on Familial Dysautonomia (FD), a severe and underserved genetic autonomic nervous system disease. The company is advancing a dual-platform strategy, developing both small molecule correctors of the underlying ELP1 splicing defect and an AAV-based gene replacement therapy, with programs currently in the pre-clinical stage. Its unique PBC structure and deep collaboration with academic leaders and the patient community underscore a stakeholder-aligned model aimed at accelerating development and guaranteeing affordable access.
Dual-platform strategy: 1) Small molecule splicing correctors targeting ELP1 mRNA, and 2) AAV2-based gene replacement therapy for the ELP1 gene.
Funding History
1
Total raised:$27.5M
Series A$27.5MCannbit Pharmaceuticals
Opportunities
As the only company solely dedicated to Familial Dysautonomia (FD), Tikun has a clear first-mover advantage in an area of catastrophic unmet need.
The company's Public Benefit Corporation structure creates deep alignment with the patient community and may streamline clinical development and regulatory interactions.
Successful development could establish a template for mission-driven biotechs in other ultra-rare diseases.
Risk Factors
High scientific risk inherent in novel neurological therapies, particularly for a complex multi-system disease.
Significant financial risk due to the ultra-rare patient population and the company's pre-revenue, pre-clinical status, which may challenge traditional funding avenues.
Commercial sustainability risk given the PBC mandate for low-cost access, potentially requiring ongoing non-dilutive funding.
Competitive Landscape
There are no known biotechnology or pharmaceutical companies with a primary focus on developing a disease-modifying therapy for Familial Dysautonomia. Tikun Therapeutics currently faces no direct competition. The competitive landscape consists of academic research groups and the standard of care, which is purely supportive/symptomatic management. Any future competitor would be years behind Tikun's focused efforts.
